Roku Inc. Class A Common Stock vs Smith & Nephew plc — how do they compare? Roku Inc. Class A Common Stock trades at $152.85 (market cap $22.84B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Roku Inc. Class A Common Stock is far larger — about 2.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Roku Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roku Inc. Class A Common Stock for 1 Days and Smith & Nephew plc for 121 Days on average.
| ROKU | SNN | |
|---|---|---|
Market Cap | $22.84B | $11.10B |
Volume | 1,030,322 | 1,051,703 |
Sector | Media | Health |
52-Week High | $159.76 | $37.17 |
52-Week Low | $82.93 | $26.42 |
Typical Hold Time | 1 Days | 121 Days |
Enterprise Value | $20.76B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Trailing returns across standard periods
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →